A new PCSK-9 monoclonal antibody for lowering LDL-cholesterol and lipoprotein(a) in Chinese patients with familial hypercholesterolaemia [0.03%]
用于中国杂合子家族性高胆固醇血症患者降低低密度脂蛋白胆固醇和脂蛋白(a)的新型PCSK9单克隆抗体治疗研究
Seyed Saeed Tamehri Zadeh,Dick C Chan,Gerald F Watts
Seyed Saeed Tamehri Zadeh
Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis [0.03%]
急性冠脉综合征患者使用PCSK-9抑制剂疗效和安全性的系统评价和网状Meta分析
Guoying Kao,Chuan Chen,Ying Zhang et al.
Guoying Kao et al.
Background: Acute coronary syndrome (ACS) remains a leading cause of global cardiovascular morbidity and mortality, with elevated low-density lipoprotein cholesterol (LDL-C) being a key modifiable risk factor. Despite sta...
Pharmacoeconomic Aspects of Using New-Generation Drugs of the PCSK-9 Inhibitor Class and Those Utilizing the Effect of Ribonucleic Acid Interference in the Treatment of Patients With Hypercholesterolemia [0.03%]
新一代PCSK-9抑制剂类药物及利用核糖核酸干扰效应的降脂药在高胆固醇血症患者治疗中的药经济学方面的影响
A D Ermolaeva,T N Ermolaeva,K A Kokushkin
A D Ermolaeva
Aim Clinical and economic analysis of the feasibility of using new-generation drugs of the PCSK-9 inhibitor class (alirocumab and evolocumab) and the drugs that utilize in their action the effect of ribonucleic acid interference (inclisiran...
Short-term effects of PCSK-9 inhibitors on percutaneous coronary intervention in patients with acute coronary syndrome [0.03%]
PCSK-9抑制剂对急性冠脉综合征患者经皮冠状动脉介入治疗的短期影响
Dong Hyun Gim,In Young Choi,Young-Jae Ki et al.
Dong Hyun Gim et al.
Background/aims: Proprotein-converting enzyme subtilisin-kexin type 9 (PCSK9) inhibitors act more promptly and efficiently than statins and reduce the risk of cardiovascular events in patients with acute coronary syndrome...
PCSK-9 Inhibitors Can Significantly Improve the Coronary Slow Flow Caused by Elevated Lipoprotein (a) in ST-Elevation Myocardial Infarction Patients With Chronic Kidney Disease [0.03%]
PCSK-9抑制剂可显著改善ST段抬高型心肌梗死合并慢性肾脏病患者的脂蛋白(a)升高的冠状动脉慢血流
Hao Xu,Ziqing Wang,Dan Chen et al.
Hao Xu et al.
Background: Coronary slow flow and no reflow significantly predict poor prognosis in acute myocardial infarction (AMI) patients, especially those with chronic kidney disease (CKD). Early identification of factors contribu...
Bract Extract on Lipid Metabolism Disorders Through Modulation of HMG-CoA Reductase, Apo A-1, PCSK-9, p-AMPK, SREBP-2, and CYP2E1 Expression [0.03%]
Cynara scolymus L.苞叶提取物通过调节HMG-CoA还原酶、Apo A-1、PCSK-9、p-AMPK、SREBP-2和CYP2E1表达对脂质代谢紊乱的影响研究
Imane Mokhtari,Abdelaaty A Shahat,Omar M Noman et al.
Imane Mokhtari et al.
Background/Objectives: Hyperlipidemia is a major contributor to metabolic complications and tissue damage, leading to conditions such as liver steatosis, atherosclerosis, and obesity. This study aimed to investigate the effects of aqueous a...
PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease [0.03%]
PCSK-9抑制疗法可改善心血管病高危患者的内皮功能
Dennis Kannenkeril,Agnes Bosch,Julie Kolwelter et al.
Dennis Kannenkeril et al.
Background: Impaired endothelial function predicts cardiovascular events. The aim of this study was to analyze the effect of evolocumab on endothelial function in patients with cardiovascular disease. ...
Life-Threatening Reaction to Lifesaving Medication: Stepwise Approach to Severe Adverse Reactions to PCSK-9 Monoclonal Antibodies [0.03%]
威胁生命的救命药物反应：PCSK-9单克隆抗体严重不良反应的分级处理方法
Tia Bimal,Anthony Szema,Maia Pavlovic et al.
Tia Bimal et al.
Typical side effects of proprotein convertase subtilisin/kexin type 9 monoclonal antibodies including influenza-like illness and injection site reactions, are minor and well tolerated. This case, however, highlights a less common but severe...
Efficacy of Traditional Anti-lipidemic Drugs in Lowering Lipoprotein(a) Levels: A Systematic Review [0.03%]
传统降脂药物降低Lp(a)水平疗效的系统评价
Mohit Sinha,Rafik Maged,Pakeeza Tarar et al.
Mohit Sinha et al.
Keywords: antisense oligonucleotides; apheresis therapy; ascvd; lipoprotein (a); lp(a); pcsk-9 inhibitor; small interfering rna; statins. Copyright © 2024, Sinha et al.
Use and effectiveness of PCSK-9 inhibitors in heart diseases: A review [0.03%]
PCSK-9抑制剂在心血管疾病中的应用及疗效：综述研究
Nasser M Alorfi,Maan H Harbi,Maguy Saffouh El Hajj et al.
Nasser M Alorfi et al.
Proprotein Convertase Subtilisin/Kexin type-9 (PCSK-9) inhibitors have recently used in the management of different cardiac complications. Several clinical trials demonstrated their effectiveness in patients with hypercholesterolemia. Howev...
耗时 0.10126 秒，为您在
48815168
条记录里面共找到 72 篇文章 [XML]